Immunotherapy versus tyrosine kinase inhibitors in advanced hepatocellular carcinoma in first-line setting: A systematic review and meta-analysis of randomized controlled trials

被引：0
|
作者：
Carolina Marin Comini, Ana Carolina
de Sousa, Isadora Martins
Abrahao Reis, Pedro Cotta
Carvalho, Bruno Murad
Guedes Camandaroba, Marcos Pedro
机构：
[1] AC Camargo Canc Ctr, Sao Paulo, Brazil
[2] Univ Fed Rio de Janeiro, Rio De Janeiro, Brazil
[3] Fac Med Barbacena FAME FUNJOB, Lavras, Brazil
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16132
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Efficacy of transarterial therapy combined with first-line tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: a network meta-analysis
    Hu, Lingbo
    Lin, Jiangying
    Shi, Xingpeng
    Wang, Aidong
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2023, 21 (01)
  • [22] Efficacy of transarterial therapy combined with first-line tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: a network meta-analysis
    Lingbo Hu
    Jiangying Lin
    Xingpeng Shi
    Aidong Wang
    World Journal of Surgical Oncology, 21
  • [23] Treatment-related adverse events of first-line immunotherapy versus sorafenib for advanced hepatocellular carcinoma: a meta-analysis
    Rizzo, Alessandro
    Carloni, Riccardo
    Ricci, Angela Dalia
    Cusmai, Antonio
    Laforgia, Mariarita
    Calabro, Concetta
    Ungaro, Valentina
    Oreste, Donato
    Sollitto, Mario
    Palmiotti, Gennaro
    Brandi, Giovanni
    EXPERT OPINION ON DRUG SAFETY, 2023, 22 (04) : 323 - 329
  • [24] Risk of toxicity with immunotherapy-tyrosine kinase inhibitors for metastatic renal cell carcinoma: a meta-analysis of randomized controlled trials
    Rizzo, Alessandro
    Mollica, Veronica
    Santoni, Matteo
    Rosellini, Matteo
    Marchetti, Andrea
    Massari, Francesco
    FUTURE ONCOLOGY, 2022, 18 (05) : 625 - 634
  • [25] A systematic review with meta-analysis of risks and benefits of tyrosine kinase inhibitors in hepatocellular carcinoma treatment
    Martinez-Geijo, J.
    Payo-Serafin, T.
    Mendez-Blanco, C.
    Fernandez Palanca, P.
    Garcia Palomo-Perez, A.
    Ortiz de Urbina Gonzalez, J. J.
    San-Miguel, B.
    Tunon, M. J.
    Mauriz, J. L.
    ANNALS OF ONCOLOGY, 2024, 35 : S81 - S81
  • [26] Octreotide for advanced hepatocellular carcinoma: a meta-analysis of randomized controlled trials
    Guo, Tian-Kang
    Hao, Xiang-Yong
    Ma, Bin
    Yang, Ke-Hu
    Li, Yi-Ping
    Li, Hong-Ling
    Gu, Yuan-Hui
    Cai, Hui
    Liu, Ya-Li
    Li, Yuan
    Zhan, Wei-Peng
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2009, 135 (12) : 1685 - 1692
  • [27] Octreotide for advanced hepatocellular carcinoma: a meta-analysis of randomized controlled trials
    Tian-Kang Guo
    Xiang-Yong Hao
    Bin Ma
    Ke-Hu Yang
    Yi-Ping Li
    Hong-Ling Li
    Yuan-Hui Gu
    Hui Cai
    Ya-Li Liu
    Yuan Li
    Wei-Peng Zhan
    Journal of Cancer Research and Clinical Oncology, 2009, 135 : 1685 - 1692
  • [28] MICROWAVE ABLATION VERSUS RADIOFREQUENCY ABLATION FOR HEPATOCELLULAR CARCINOMA: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
    Fazli, Obaid O. F.
    Roberts, Stuart Skr
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 : 121 - 121
  • [29] Lenvatinib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
    Wang, Shijie
    Wang, Yiting
    Yu, Jiangtao
    Wu, Huaxing
    Zhou, Yanming
    CANCERS, 2022, 14 (22)
  • [30] First-line systemic treatment for hepatocellular carcinoma: A systematic review and network meta-analysis
    Ciliberto, Domenico
    Carid, Giulio
    Staropoli, Nicoletta
    Romeo, Caterina
    Arillotta, Grazia Maria
    Napoli, Cristina
    Gervasi, Luigia
    Luciano, Francesco
    Riillo, Caterina
    Tassone, Pierfrancesco
    Tagliaferri, Pierosandro
    HELIYON, 2023, 9 (08)
12345